HilleVax (HLVX) Competitors

HilleVax (NASDAQ:HLVX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Which has more volatility and risk, HLVX or RNAC?

HilleVax has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Do institutionals and insiders believe in HLVX or RNAC?

86.4% of HilleVax shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 71.1% of HilleVax shares are owned by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media prefer HLVX or RNAC?

In the previous week, Cartesian Therapeutics had 2 more articles in the media than HilleVax. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 0 mentions for HilleVax. Cartesian Therapeutics' average media sentiment score of 0.30 beat HilleVax's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
HilleVax	Neutral
Cartesian Therapeutics	Neutral

Does the MarketBeat Community prefer HLVX or RNAC?

Cartesian Therapeutics received 28 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 95.00% of users gave Cartesian Therapeutics an outperform vote while only 55.56% of users gave HilleVax an outperform vote.

Company	Underperform	Outperform
HilleVax	Outperform Votes 10 55.56%	Underperform Votes 8 44.44%
Cartesian Therapeutics	Outperform Votes 38 95.00%	Underperform Votes 2 5.00%

Is HLVX or RNAC more profitable?

HilleVax has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat HilleVax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HilleVax	N/A	-67.27%	-51.99%
Cartesian Therapeutics	-510.72%	N/A	-6.03%

Do analysts prefer HLVX or RNAC?

HilleVax currently has a consensus price target of $3.00, suggesting a potential upside of 77.51%. Cartesian Therapeutics has a consensus price target of $42.14, suggesting a potential upside of 301.36%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than HilleVax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HilleVax	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cartesian Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Which has better earnings and valuation, HLVX or RNAC?

HilleVax has higher earnings, but lower revenue than Cartesian Therapeutics. HilleVax is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HilleVax	N/A	N/A	-$123.57M	-$3.00	-0.56
Cartesian Therapeutics	$38.91M	6.99	-$219.71M	-$52.83	-0.20

Summary

Cartesian Therapeutics beats HilleVax on 12 of the 17 factors compared between the two stocks.